Work

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.324.324

Authors: Anthony S. Stein, Roland B. Walter, Harry P Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E Lancet, Farhad Ravandi, Tibor J. Kovacsovics, Daniel J. DeAngelo, Dale Bixby, Stefan Faderl, Anand P Jillella, Megan M. O'Meara, Baiteng Zhao, Eytan M Stein

Institutions: City Of Hope National Medical Center, Fred Hutch Cancer Center, University of Alabama at Birmingham, Harvard University, Massachusetts General Hospital, Cleveland Clinic, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, University of Utah, Huntsman Cancer Institute, Dana-Farber Cancer Institute, University of Michigan, U-M Rogel Cancer Center, Hackensack University Medical Center, Winship Cancer Institute, Seagen (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2530105263

FWCI: 6.334

Cites:

Cited by: 29

Related to: 10